NCT06825702 - Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Macular Edema

Interventions

DRUG

KIO-104

KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

Trial Locations (4)

2001

RECRUITING

Sydney Eye Hospital, Sydney

3002

RECRUITING

Centre for Eye Research Australia, East Melbourne

5000

NOT_YET_RECRUITING

Royal Adelaide Hospital, Adelaide

6009

RECRUITING

Lions Eye Institute Limited, Nedlands